Evidence map›Paper›PMID 19651774›Full record

ArticleThe Journal of biological chemistry2009

Wnt-5a-induced phosphorylation of DARPP-32 inhibits breast cancer cell migration in a CREB-dependent manner.

Christian Hansen, Jillian Howlin, Anders Tengholm, Oleg Dyachok, Wolfgang F Vogel, Angus C Nairn, Paul Greengard, Tommy Andersson

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 79 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Wnt/β-catenin signaling in cancers and targeted therapies.Signal transduction and targeted therapy · 2021
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. WNT5A as a therapeutic target in breast cancer.Cancer metastasis reviews · 2018
    Review
  15. Frizzled Receptors as Potential Therapeutic Targets in Human Cancers.International journal of molecular sciences · 2018
    Review
  16. Article
  17. Article
  18. Multiple Roles of WNT5A in Breast Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2016
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Christian HansenExperimental Pathology, Department of Laboratory Medicine, Lund University, CRC, 205 02 Malmö, Sweden.
Jillian Howlin
Anders Tengholm
Oleg Dyachok
Wolfgang F Vogel
Angus C Nairn
Paul Greengard
Tommy Andersson
Lund University · SEUppsala University · SERockefeller University · USUniversity of Toronto · CAYale University · US

Funding

THE ROLE OF DARPPS IN THE ACUTE AND CHRONIC EFFECTS OF COCAINE AND AMPHETAMINEP01DA010044 · NIDA · ROCKEFELLER UNIVERSITY · PI NAIRN, ANGUS C. · 1996 to 2015
$23.6M
Transgenic Core - Greengard (pgs. 218 - 235)P50MH074866 · NIMH · ROCKEFELLER UNIVERSITY · PI GREENGARD, PAUL · 2005 to 2009
$11.6M
NIDA NIH HHS P01 DA010044NIMH NIH HHS MH074866NIMH NIH HHS P50 MH074866
6 · The paper itself

Abstract

Tumor cell migration plays a central role in the process of cancer metastasis. We recently identified dopamine and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) as an antimigratory phosphoprotein in breast cancer cells. Here we link this effect of DARPP-32 to Wnt-5a signaling by demonstrating that recombinant Wnt-5a triggers cAMP elevation at the plasma membrane and Thr34-DARPP-32 phosphorylation in MCF-7 cells. In agreement, both protein kinase A (PKA) inhibitors and siRNA-mediated knockdown of Frizzled-3 receptor or Galpha(s) expression abolished Wnt-5a-induced phosphorylation of DARPP-32. Furthermore, Wnt-5a induced DARPP-32-dependent inhibition of MCF-7 cell migration. Phospho-Thr-34-DARPP-32 interacted with protein phosphatase-1 (PP1) and potentiated the Wnt-5a-mediated phosphorylation of CREB, a well-known PP1 substrate, but had no effect on CREB phosphorylation by itself. Moreover, inhibition of the Wnt-5a/DARPP-32/CREB pathway, by expression of dominant negative CREB (DN-CREB), diminished the antimigratory effect of Wnt-5a-induced phospho-Thr-34-DARPP-32. Phalloidin-staining revealed that that the presence of phospho-Thr-34-DARPP-32 in MCF-7 cells results in reduced filopodia formation. In accordance, the activity of the Rho GTPase Cdc42, known to be crucial for filopodia formation, was reduced in MCF-7 cells expressing phospho-Thr-34-DARPP-32. The effects of DARPP-32 on cell migration and filopodia formation could be reversed in T47D breast cancer cells that were depleted of their endogenous DARPP-32 by siRNA targeting. Consequently, Wnt-5a activates a Frizzled-3/Galpha(s)/cAMP/PKA signaling pathway that triggers a DARPP-32- and CREB-dependent antimigratory response in breast cancer cells, representing a novel mechanism whereby Wnt-5a can inhibit breast cancer cell migration.

Indexed as

Cell MovementAnimalsBreast NeoplasmsCarrier ProteinsCell Cycle ProteinsCell Line, TumorCyclic AMPCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinDNA-Binding ProteinsDopamine and cAMP-Regulated Phosphoprotein 32Frizzled ReceptorsHumansMiceNuclear ProteinsPhosphorylationCarrier ProteinsCell Cycle ProteinsCyclic AMPCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinDNA-Binding ProteinsDopamine and cAMP-Regulated Phosphoprotein 32Frizzled ReceptorsFZD3 protein, humanNuclear ProteinsPAGR1 protein, humanPhosphothreonineProtein Phosphatase 1Proto-Oncogene ProteinsReceptors, G-Protein-CoupledWnt-5a ProteinWNT5A protein, humanWnt Proteins

Identifiers

PMID19651774
PMCPMC2785682
OpenAlexW2066583853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.